TNGX Q2 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-84.0% YoY

Gross Profit

$3M80.4% margin

Operating Income

-$41M-1287.9% margin

Net Income

-$39M-1221.4% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

-41.0%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$238M

Total Liabilities

$103M

Stockholders' Equity

$135M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$20M	-84.0%
Gross Profit	$3M	$20M	-87.1%
Operating Income	-$41M	-$30M	-38.6%
Net Income	-$39M	-$26M	-52.1%

Revenue Segments

Collaboration Revenue

$3M100%